a comparative study was done in 59 recently diagnosed stage d2 prostatic cancer patients treated with either long-term gnrh-a ( buserelin ) ( n = 42 ) or with orchiectomy ( n = 17 ) and followed up for three years .
C0023610
gnrh
C0006456
buserelin